190 related articles for article (PubMed ID: 35941895)
1. Construction and Validation of Prediction Model of Severe Abdominal Pain Post-Transarterial Chemoembolization in Patients with HBV-Associated Primary Liver Cancer.
Yang Y; Chen S; Yan Z; Jiao Y; Yan X; Li Y
Comput Math Methods Med; 2022; 2022():5203166. PubMed ID: 35941895
[TBL] [Abstract][Full Text] [Related]
2. Predictive model for acute abdominal pain after transarterial chemoembolization for liver cancer.
Bian LF; Zhao XH; Gao BL; Zhang S; Ge GM; Zhan DD; Ye TT; Zheng Y
World J Gastroenterol; 2020 Aug; 26(30):4442-4452. PubMed ID: 32874056
[TBL] [Abstract][Full Text] [Related]
3. Establishment of a predictive model for short-term efficacy of transcatheter arterial chemoembolization treatment in hepatocellular carcinoma and its clinical application.
Wei J; Wang Z
J Cancer Res Ther; 2019; 15(4):941-946. PubMed ID: 31436256
[TBL] [Abstract][Full Text] [Related]
4. Predictive factors of severe abdominal pain during and after transarterial chemoembolization for hepatocellular carcinoma.
Pachev A; Raynaud L; Paulatto L; Dioguardi Burgio M; Roche V; Garcia Alba C; Sibert A; Lagadec M; Kavafyan-Lasserre J; Paugam-Burtz C; Vilgrain V; Ronot M
Eur Radiol; 2021 May; 31(5):3267-3275. PubMed ID: 33123789
[TBL] [Abstract][Full Text] [Related]
5. Postintervention Interleukin-6 (IL-6) Level, Rather than the Pretreatment or Dynamic Changes of IL-6, as an Early Practical Marker of Tumor Response in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
Wu Y; Fan W; Xue M; Zhong B; Zhang S; Wang Y; Yao W; Zhao Y; Li J
Oncologist; 2019 Dec; 24(12):e1489-e1495. PubMed ID: 31249138
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of TACE+Radiofrequency Ablation+Sorafenib in the Treatment of Patients with Recurrent Liver Cancer and Construction of Prediction Model.
Sun A; Chen S; Lin M; Zhou D; Zhang H; Sun C; Wang P
Comput Math Methods Med; 2022; 2022():6879035. PubMed ID: 36118840
[TBL] [Abstract][Full Text] [Related]
7. Transcatheter arterial chemoembolization combined with interferon-α is safe and effective for patients with hepatocellular carcinoma after curative resection.
Zuo CH; Xia M; Liu JS; Qiu XX; Lei X; Xu RC; Liu HC; Li JL; Li YG; Li QL; Xiao H; Hong Y; Wang XH; Zhu HZ; Wu QF; Burns M; Liu C
Asian Pac J Cancer Prev; 2015; 16(1):245-51. PubMed ID: 25640360
[TBL] [Abstract][Full Text] [Related]
8. Intraarterial contrast-enhanced ultrasound to predict the short-term tumour response of hepatocellular carcinoma to Transarterial chemoembolization with Lipiodol.
Bo J; Peng H; LianHua Z; Xiang F; YuKun L
BMC Cancer; 2021 Nov; 21(1):1171. PubMed ID: 34727882
[TBL] [Abstract][Full Text] [Related]
9. Factors influencing postembolization syndrome in patients with hepatocellular carcinoma undergoing first transcatheter arterial chemoembolization.
He JJ; Yin XX; Wang T; Chen MY; Li XL; Yang XJ; Shao HY
J Cancer Res Ther; 2021 Jul; 17(3):777-783. PubMed ID: 34269313
[TBL] [Abstract][Full Text] [Related]
10. Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization.
Wang ZX; Li J; Wang EX; Xia DD; Bai W; Wang QH; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH
World J Gastroenterol; 2020 Apr; 26(15):1805-1819. PubMed ID: 32351295
[TBL] [Abstract][Full Text] [Related]
11. Overweight with HBV infection limited the efficacy of TACE in hepatocellular carcinoma by inhibiting the upregulated HMGB1.
Sun YD; Zhang H; Chen YQ; Wu CX; Chen ML; Xu HR; Wang S; Liu JZ; Han JJ
BMC Cancer; 2021 Sep; 21(1):1063. PubMed ID: 34583662
[TBL] [Abstract][Full Text] [Related]
12. Validation and evaluation of clinical prediction systems for first and repeated transarterial chemoembolization in unresectable hepatocellular carcinoma: A Chinese multicenter retrospective study.
Wang ZX; Wang EX; Bai W; Xia DD; Mu W; Li J; Yang QY; Huang M; Xu GH; Sun JH; Li HL; Zhao H; Wu JB; Yang SF; Li JP; Li ZX; Zhang CQ; Zhu XL; Zheng YB; Wang QH; Li J; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH; On Behalf Of China Hcc-Tace Study Group
World J Gastroenterol; 2020 Feb; 26(6):657-669. PubMed ID: 32103874
[TBL] [Abstract][Full Text] [Related]
13. Prognostic nomogram for post-surgical treatment with adjuvant TACE in hepatitis B virus-related hepatocellular carcinoma.
Hu H; Han XK; Long XR; Fan J; Yan ZP; Wang JH; Liu R
Oncotarget; 2016 Sep; 7(36):58302-58314. PubMed ID: 27506942
[TBL] [Abstract][Full Text] [Related]
14. Construction of pain prediction model for patients undergoing hepatic arterial chemoembolization.
Song PW; Liu YH; Wang T; Yu L; Liu JL
World J Surg Oncol; 2023 Mar; 21(1):100. PubMed ID: 36941629
[TBL] [Abstract][Full Text] [Related]
15. The predictive values of serum dickkopf-1 and circulating tumor cells in evaluating the efficacy of transcatheter arterial chemoembolization treatment on hepatocellular carcinoma.
Wu X; Yang C; Yu H; Cao F; Shan Y; Zhao W
Medicine (Baltimore); 2019 Jul; 98(30):e16579. PubMed ID: 31348291
[TBL] [Abstract][Full Text] [Related]
16. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting.
Karalli A; Teiler J; Haji M; Seth E; Brismar TB; Wahlin S; Axelsson R; Stål P
Scand J Gastroenterol; 2019 Jul; 54(7):905-912. PubMed ID: 31287338
[No Abstract] [Full Text] [Related]
17. Prognostic Value of TP53 Mutation for Transcatheter Arterial Chemoembolization Failure/Refractoriness in HBV-Related Advanced Hepatocellular Carcinoma.
Xue M; Wu Y; Fan W; Guo J; Wei J; Wang H; Tan J; Wang Y; Yao W; Zhao Y; Li J
Cancer Res Treat; 2020 Jul; 52(3):925-937. PubMed ID: 32229792
[TBL] [Abstract][Full Text] [Related]
18. Risk of hepatitis B exacerbation is low after transcatheter arterial chemoembolization therapy for patients with HBV-related hepatocellular carcinoma: report of a prospective study.
Park JW; Park KW; Cho SH; Park HS; Lee WJ; Lee DH; Kim CM
Am J Gastroenterol; 2005 Oct; 100(10):2194-200. PubMed ID: 16181368
[TBL] [Abstract][Full Text] [Related]
19. Effects of transarterial chemoembolization combined with antiviral therapy on HBV reactivation and liver function in HBV-related hepatocellular carcinoma patients with HBV-DNA negative.
Wang K; Jiang G; Jia Z; Zhu X; Ni C
Medicine (Baltimore); 2018 Jun; 97(22):e10940. PubMed ID: 29851833
[TBL] [Abstract][Full Text] [Related]
20. Nomogram for individualized prediction of recurrence after postoperative adjuvant TACE for hepatitis B virus-related hepatocellular carcinoma.
Jiang J; Hu H; Liu R; Wang JH; Long XR; Fan J; Yan ZP
Medicine (Baltimore); 2017 Aug; 96(32):e7390. PubMed ID: 28796032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
